Literature DB >> 16132347

Comparison of (-)-epigallocatechin-3-gallate elicited liver and small intestine gene expression profiles between C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice.

Guoxiang Shen1, Changjiang Xu, Rong Hu, Mohit R Jain, Sujit Nair, Wen Lin, Chung S Yang, Jefferson Y Chan, A-N Tony Kong.   

Abstract

PURPOSE: This study was conducted to study global gene expression profiles elicited by (-)-epigallocatechin-3-gallate (EGCG) in mouse liver and small intestine, as well as to identify EGCG-regulated Nrf2-dependent genes.
METHODS: C57BL/6J and C57BL/6J/Nrf2(-/-) mice were given an oral dose of EGCG at 200 mg/kg or treated with vehicle. Both liver and small intestine were collected 3 h and 12 h after treatment. Total RNA was extracted from the tissues and gene expression profiles were analyzed using Affymetrix mouse genome 430 2.0 array and GeneSpring 6.1 software. Microarray data were validated using quantitative real-time reverse transcription-PCR chain reaction analysis.
RESULTS: Genes that were either induced or suppressed more than two fold by EGCG treatment compared with vehicle treatment in the same genotype group were filtered using the GeneSpring software. Among these well-defined genes, 671 EGCG-regulated Nrf2-dependent genes and 256 EGCG-regulated Nrf2-independent genes were identified in liver, whereas 228 EGCG-regulated Nrf2-dependent genes and 98 EGCG-regulated Nrf2-independent genes were identified in the small intestine. Based on their biological functions, these genes mainly fall into the category of ubiquitination and proteolysis, electron transport, detoxification, transport, cell growth and apoptosis, cell adhesion, kinase and phosphatases, and transcription factors.
CONCLUSIONS: Genes expressed in mouse liver are more responsive to oral treatment of EGCG than those expressed in small intestine. EGCG could regulate many genes in both organs in an Nrf2-dependent manner. The identification of genes related to detoxification, transport, cell growth and apoptosis, cell adhesion, kinase, and transcription regulated by EGCG not only provide potential novel insight into the effect of EGCG on global gene expression and chemopreventive effects, but also point to the potential role of Nrf2 in these processes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16132347     DOI: 10.1007/s11095-005-7546-8

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  73 in total

1.  Protective effect of green tea on the risks of chronic gastritis and stomach cancer.

Authors:  V W Setiawan; Z F Zhang; G P Yu; Q Y Lu; Y L Li; M L Lu; M R Wang; C H Guo; S Z Yu; R C Kurtz; C C Hsieh
Journal:  Int J Cancer       Date:  2001-05-15       Impact factor: 7.396

2.  High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes.

Authors:  A Enomoto; K Itoh; E Nagayoshi; J Haruta; T Kimura; T O'Connor; T Harada; M Yamamoto
Journal:  Toxicol Sci       Date:  2001-01       Impact factor: 4.849

3.  Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia.

Authors:  Shujun Liu; Tiansheng Shen; Lenguyen Huynh; Marko I Klisovic; Laura J Rush; Jamie L Ford; Jianhua Yu; Brian Becknell; Yu Li; Chunhui Liu; Tamara Vukosavljevic; Susan P Whitman; Kun-Sang Chang; John C Byrd; Danilo Perrotti; Christoph Plass; Guido Marcucci
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

4.  Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate.

Authors:  N Ahmad; P Cheng; H Mukhtar
Journal:  Biochem Biophys Res Commun       Date:  2000-08-28       Impact factor: 3.575

5.  Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate.

Authors:  Y C Liang; S Y Lin-Shiau; C F Chen; J K Lin
Journal:  J Cell Biochem       Date:  1999-10-01       Impact factor: 4.429

6.  NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development.

Authors:  K Chan; R Lu; J C Chang; Y W Kan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

7.  Reduction of hepatic ischemia/reperfusion-induced injury by a specific ROCK/Rho kinase inhibitor Y-27632.

Authors:  Fusao Ikeda; Hiroaki Terajima; Yasuyuki Shimahara; Tadashi Kondo; Yoshio Yamaoka
Journal:  J Surg Res       Date:  2003-02       Impact factor: 2.192

8.  Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells.

Authors:  Koen Brusselmans; Ellen De Schrijver; Walter Heyns; Guido Verhoeven; Johannes V Swinnen
Journal:  Int J Cancer       Date:  2003-10-10       Impact factor: 7.396

9.  Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines.

Authors:  Ming Zhu Fang; Yimin Wang; Ni Ai; Zhe Hou; Yi Sun; Hong Lu; William Welsh; Chung S Yang
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

10.  Mechanisms of the inhibitory effects of epigallocatechin-3 gallate on platelet-derived growth factor-BB-induced cell signaling and mitogenesis.

Authors:  Artur-Aron Weber; Thomas Neuhaus; Romanita Adriana Skach; Jürgen Hescheler; Hee-Yul Ahn; Karsten Schrör; Yon Ko; Agapios Sachinidis
Journal:  FASEB J       Date:  2003-11-20       Impact factor: 5.191

View more
  56 in total

1.  Regulation of Nrf2- and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells.

Authors:  Sujit Nair; Avantika Barve; Tin-Oo Khor; Guo-xiang Shen; Wen Lin; Jefferson Y Chan; Li Cai; Ah-Ng Kong
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 2.  Toxicogenomics in drug discovery and drug development: potential applications and future challenges.

Authors:  Tin Oo Khor; Sherif Ibrahim; Ah-Ng Tony Kong
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

3.  NF-kappaB and Nrf2 as prime molecular targets for chemoprevention and cytoprotection with anti-inflammatory and antioxidant phytochemicals.

Authors:  Young-Joon Surh; Hye-Kyung Na
Journal:  Genes Nutr       Date:  2008-02       Impact factor: 5.523

Review 4.  Nrf2 at the heart of oxidative stress and cardiac protection.

Authors:  Qin M Chen; Anthony J Maltagliati
Journal:  Physiol Genomics       Date:  2017-11-29       Impact factor: 3.107

Review 5.  Nuclear factor-erythroid 2-related factor 2 as a chemopreventive target in colorectal cancer.

Authors:  Constance Lay Lay Saw; Ah-Ng Tony Kong
Journal:  Expert Opin Ther Targets       Date:  2011-01-25       Impact factor: 6.902

6.  Nrf2 protects human bladder urothelial cells from arsenite and monomethylarsonous acid toxicity.

Authors:  Xiao-Jun Wang; Zheng Sun; Weimin Chen; Kylee E Eblin; Jay A Gandolfi; Donna D Zhang
Journal:  Toxicol Appl Pharmacol       Date:  2007-08-07       Impact factor: 4.219

7.  Enzymatic metabolites of lycopene induce Nrf2-mediated expression of phase II detoxifying/antioxidant enzymes in human bronchial epithelial cells.

Authors:  Fuzhi Lian; Xiang-Dong Wang
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

Review 8.  Mechanisms of body weight reduction and metabolic syndrome alleviation by tea.

Authors:  Chung S Yang; Jinsong Zhang; Le Zhang; Jinbao Huang; Yijun Wang
Journal:  Mol Nutr Food Res       Date:  2015-12-09       Impact factor: 5.914

9.  Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis.

Authors:  S Nair; S T Doh; J Y Chan; A-N Kong; L Cai
Journal:  Br J Cancer       Date:  2008-12-02       Impact factor: 7.640

10.  Epigallocatechin activates haem oxygenase-1 expression via protein kinase Cdelta and Nrf2.

Authors:  Richard M Ogborne; Stuart A Rushworth; Maria A O'Connell
Journal:  Biochem Biophys Res Commun       Date:  2008-06-27       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.